Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:: a systematic overview of data from individual patients
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:: a systematic overview of data from individual patients
复制标题
DOI：
10.1016/s0140-6736(00)02212-1
复制
发表时间：
2000-05-06
期刊：
影响因子：
168.9
通讯作者：
Braunwald, E
中科院分区：
文献类型：
--
作者：
Flather, MD;Yusuf, S;Braunwald, E
背景：我们进行了一项前瞻性的系统性综述的基础上，从5个长期的随机试验，评估左心室功能障碍或心力衰竭患者的血管紧张素转换酶（ACE）抑制剂的患者的数据。方法三个试验招募急性心肌梗死后一周内的患者。数据进行了合并使用的Peto-Yusuf方法。结果总体12 763例患者被随机分配治疗或安慰剂，并随访平均35个月。在三项梗死后试验（n=5966）中，ACE抑制剂组的死亡率低于安慰剂组（702/2995 [23.4%] Vs 866/2971 [29.1%];比值比0.74 [95%CI 0.66-0.83]），心力衰竭再入院率也是如此（355 [11.9%] vs 460 [15.55%]; 0.73 [0.63-0.85]），再梗死（324 [10.8%] vs 391 [13.2%]; 0.80 [0.69-0.94]），或这些事件的复合事件（1049 [35.0%] vs 1244 [41.9%]; 0.75 [0.67-0.83];所有P
Background We undertook a prospective systematic overview based on data from individual patients from five long-term randomised trials that assessed inhibitors of angiotensin-converting enzyme (ACE) in patients with left-ventricular dysfunction or heart failure.Methods Three of the trials enrolled patients within a week after acute myocardial infarction. Data were combined by use of the Peto-Yusuf method.Findings Overall 12 763 patients were randomly assigned treatment or placebo and followed up for an average of 35 months. In the three post-infarction trials (n=5966), mortality was lower with ACE inhibitors than with placebo (702/2995 [23.4%] Vs 866/2971 [29.1%]; odds ratio 0.74 [95% CI 0.66-0.83]), as were the rates of readmission for heart failure (355 [11.9%] vs 460 [15.55%]; 0.73 [0.63-0.85]), reinfarction (324 [10.8%] vs 391 [13.2%]; 0.80 [0.69-0.94]), or the composite of these events (1049 [35.0%] vs 1244 [41.9%]; 0.75 [0.67-0.83]; all p